Gossamer Bio reports Thursday with one fact dominating the setup: nearly 17% of the free float is sold short. That is a meaningful bearish overhang for a stock trading at $0.34, down 21% over the past month despite a modest 4% recovery in the latest week.
Short sellers have been lightening up, however — and that nuance matters. Short interest fell roughly 1.3% over the past week to around 38.8 million shares, trimming from a slightly higher base earlier in May. The borrow market is not tight. Availability has actually loosened sharply, climbing to 154% — meaning the lending pool holds more than one and a half shares available for every share already borrowed. Cost to borrow is a modest 1.3% annualised, edging up 18% on the week but nowhere near squeeze territory. The ORTEX short score of 65, while elevated, has drifted down from a recent peak near 68 earlier this month. Options sentiment is resolutely call-skewed: the put/call ratio at 0.15 sits close to its 20-day average and near the 52-week low, suggesting no rush to hedge downside through the derivatives market.
The core debate is clinical and financial rather than technical. Bulls point to a remaining pipeline in immunology and inflammation, and the hope that regulatory dialogue — or a positive read-across from a competitor — could re-rate the stock off its lows. HC Wainwright maintained its Buy with a $5 target in early March, and Oppenheimer kept Outperform even as it trimmed its target to $3. Bears have a blunter case: the Phase 3 failure for seralutinib in pulmonary arterial hypertension dismantled the company's lead asset, and a series of downgrades in February and March reflect the wreckage. Barclays cut from Overweight to Underweight in late February, dropping its target from $9 to $0.30 — almost exactly where the stock now trades. Cantor Fitzgerald downgraded to Neutral in late March. The consensus mean target of $1.56 implies theoretical upside from current levels, but the dispersion between $0.30 and $5.00 targets tells the real story: analysts disagree sharply on whether any recovery path exists. Note that several of the older analyst targets were set before the seralutinib data readout and should be treated with caution — the post-February landscape is materially different.
One genuine point of interest in the ownership data is the emergence of new money. Kalehua Capital Management initiated a position of over 10 million shares in Q1 2026, appearing for the first time among the top holders. Balyasny and Qube Research also added meaningful new positions in the same quarter. Offsetting that, Octagon Capital cut its stake by over 7 million shares. BlackRock and Vanguard remain the two largest institutional holders, with modest additions. The insider log is stale — the most recent disclosed trade dates to August 2025 — so no fresh executive signal is available heading into this print.
Thursday's report is therefore less a question of quarterly mechanics and more a test of whether management can articulate a credible next step for the pipeline, and whether the company's cash runway extends far enough to give any remaining assets a chance to reach data.
See the live data behind this article on ORTEX.
Open GOSS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
